EQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution | Brandaktuell - Nachrichten aus allen Bereichen

EQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution

0 129

EQS Voting Rights Announcement: Marinomed Biotech AG
Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG
with the objective of Europe-wide distribution

15.04.2024 / 16:00 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News – a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

══════════════════════════════════════════════════════════════════════════

Major holdings notification pursuant to Sec. 130 to 134 BörseG 2018

 

Wien,  15.4.2024

 

Overview

☐ Notification made after deadline

Caution: In case of violations of major holdings notification rules,
please pay attention to Section 137 BörseG 2018 (Suspension of voting
rights)
 

1. Issuer: Marinomed Biotech AG

2. Reason for the notification: Acquisition or disposal of voting rights

3. Person subject to notification obligation
Name: LLB Invest Kapitalanlagegesellschaft m.b.H.
City: Wien
Country: Österreich

4. Name of shareholder(s): 

5. Date on which the threshold was crossed or reached: 15.4.2024

6. Total positions

    % of voting rights    
% of voting through   Total number
rights financial/other Total of of voting
attached to instruments (7.B.1 + both in rights of
shares (7.A) 7.B.2) % (7.A + issuer
7.B)
Resulting        
situation on the 5,02 % 0,00 % 5,02 % 1 540 530
date on which
threshold was
crossed / reached
Position of        
previous 4,01 % 0,00 % 4,01 %
notification (if
applicable)

Details

7. Notified details of the resulting situation:

A: Voting rights attached to shares
ISIN Code Number of voting rights % of voting rights
Direct Indirect Direct Indirect
(Sec 130 BörseG 2018) (Sec 133 BörseG (Sec 130 (Sec 133
2018) BörseG 2018) BörseG
2018)
ATMARIONOMED6 77 374 0 5,02 % 0,00 %
SUBTOTAL A 77 374 5,02 %

 

B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1
BörseG 2018
Type of Expiration Date Exercise Number of voting % of voting
instrument Period rights that may be rights
acquired if the
instrument is
exercised
         
    SUBTOTAL B.1    

 

B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2
BörseG 2018
Type of Expiration Exercise Physical / Number % of
instrument Date Period Cash of voting
Settlement voting rights
rights
           
      SUBTOTAL B.2    

 

8. Information in relation to the person subject to the notification
obligation:

☒ Person subject to the notification obligation is not controlled by any
natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer.

☐ Full chain of controlled undertakings through which the voting rights
and/or the financial/other instruments are effectively held starting with
the ultimate controlling natural person or legal entity:

 

9. In case of proxy voting

Date of general meeting: –

Voting rights after general meeting: – is equivalent to – voting rights.

 

10. Sonstige Kommentare:

Die LLB Invest Kapitalanlagegesellschaft m.b.H. hält genannte Aktien als
Verwaltungsgesellschaft (KAG) von vier Investmentfonds. Es gilt
hinsichtlich der Zurechnung/Kontrolle die Ausnahme nach § 134 Abs 2 BörseG
und § 8 TransV 2018.
 

Wien am  15.4.2024

 

══════════════════════════════════════════════════════════════════════════

15.04.2024 CET/CEST

══════════════════════════════════════════════════════════════════════════

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Internet: www.marinomed.com

 
End of News EQS News Service

1880665  15.04.2024 CET/CEST

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
(C) Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender. Marinomed Biotech AG

Hinterlasse eine Antwort

Deine Email-Adresse wird nicht veröffentlicht.